The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

Early prostate cancer screening protocol for germline pathogenic variant carriers (BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2, TP53)

The PATROL study describes an early prostate cancer screening protocol for carriers of germline pathogenic variants in NCCN high-risk genes (BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2, TP53). The study evaluates optimal screening modalities — age-adjusted PSA thresholds, prostate imaging — to refine current strategies for this genetically high-risk population.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

PCa screening in germline carriers remains one of the most debated questions in male oncogenetics. PATROL provides a prospective framework to evaluate optimal strategies — urgently needed as multigene panel testing identifies increasing numbers of BRCA2 and CHEK2 carriers.

Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 7/10